TWiV 901: COVID-19 clinical update #115 with Dr. Daniel Griffin

May 21, 2022

In COVID-19 clinical update #115, Dr. Griffin reviews cross-variant immunity without vaccination, EUA for boosters in 5-11 year olds, B.1.1.529 attack rate, scent dogs, Omicron and pets, Paxlovid, Veklury, Fluvoxamine, antigen positivity after isolation, inflammasome activation and severe disease, and GI persistence and fecal shedding.

Click arrow to play
Download TWiV 901 (36 MB .mp3, 60 min)
Subscribe (free): Apple PodcastsGoogle PodcastsRSSemail

Become a patron of TWiV!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to

Leave a Reply

Your email address will not be published. Required fields are marked *

2 comments on “TWiV 901: COVID-19 clinical update #115 with Dr. Daniel Griffin

  1. Callie May 21, 2022

    Paxlovid…family member took it after trip across country, symptoms on day 4. Tested positive. Teledoc prescribed it; Two years ago, Z-pack worked in 5 days. This time, doc refused that med. Seemed better but now two days after pills gone going back to when it started: Congested, fatigue. But since it’s experimental is it really worth taking another round? Not so much.

  2. H. Bradford Hawley, MD May 22, 2022

    Dofetilide, brand name Tikosyn (Pfizer), is a potassium channel blocker given for the prevention of atrial fibrillation and it metabolized through the P450 CYP3A4 pathway. Increased levels lead to prolonged QT intervals and torsades de pointes, a difficult to treat and potentially fatal ventricular arrhythmia. Dofetilide is not included specifically on the FDA list of Paxlovid drug interactions. Please mention this as it is a potentially fatal interaction with a drug that is most often given to elderly patients which would also be eligible for Paxlovid. These patients should be given remdesivir or molnupiravir.